Threonine

Threonine

SCHEMBL5082569

CC(O)C(N)C(=O)O.CCOCC

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 2/20 0.46
SLC1A3 P43003 6/20 0.40
SLC1A2 P43004 6/20 0.40
SLC1A1 P43005 6/20 0.40
USP2 O75604 1/20 0.38
SLCO1B1 Q9Y6L6 1/20 0.38
GABRP O00591 2/20 0.37
GABRD O14764 2/20 0.37
GABRA1 P14867 2/20 0.37
GABRB1 P18505 2/20 0.37
GABRG2 P18507 2/20 0.37
GABRB3 P28472 2/20 0.37
GABRA5 P31644 2/20 0.37
GABRA3 P34903 2/20 0.37
GABRA2 P47869 2/20 0.37
GABRB2 P47870 2/20 0.37
GABRA4 P48169 2/20 0.37
GABRE P78334 2/20 0.37
GABRA6 Q16445 2/20 0.37
GABRG1 Q8N1C3 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Valine SCHEMBL3824999 0.84 SLC7A5 (0.68) SLC7A5SLC1A3SLC1A2SLC1A1USP2
Threonine SCHEMBL563849 0.84 SLC7A5 (0.52) SLC7A5SLC1A3SLC1A2SLC1A1USP2
Threonine SCHEMBL6038228 0.83 SLC7A5 (0.63) SLC7A5SLC1A3SLC1A2SLC1A1USP2
Threonine SCHEMBL16111860 0.83 SLC7A5 (0.63) SLC7A5SLC1A3SLC1A2SLC1A1USP2
Threonine SCHEMBL18050155 0.83 SLC7A5 (0.63) SLC7A5SLC1A3SLC1A2SLC1A1USP2
Threonine SCHEMBL18050157 0.83 SLC7A5 (0.63) SLC7A5SLC1A3SLC1A2SLC1A1USP2
Threonine SCHEMBL117301 0.83
Threonine SCHEMBL14946556 0.83
Threonine SCHEMBL92730 0.83
Threonine SCHEMBL9461237 0.83 SLC7A5 (0.63) SLC7A5SLC1A3SLC1A2SLC1A1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1976873-A2 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS Brystol-Myers Squibb Company (US) 2008-10-08 EP disclosed
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY 2007-10-11 US disclosed
WO-2007082264-A2 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-07-19 WO disclosed
US-20030114362-A1 Penta-or tetrapeptide binding to somatostatin receptors and the use of the same NOVASPIN BIOTECH GMBH (DE) 2003-06-19 US disclosed
WO-2002100885-A2 A PENTA- OR TETRAPEPTIDE BINDING TO SOMATOSTATIN RECEPTORS AND THE USE OF THE SAME NOVASPIN BIOTECH GMBH (DE) 2002-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS GLP1R, GIPR, IAPP SLC7A5 2674/4885SLC1A3 2595/4885SLC1A2 3742/4885
US-20030114362-A1 Penta-or tetrapeptide binding to somatostatin receptors and the use of the same SSTR5, SSTR3, SCTR SLC7A5 291/4885SLC1A3 564/4885SLC1A2 928/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.